Loading…

Protection by NMDA Antagonists Against Selective Cell Loss Following Transient Ischaemia

We have administered antagonists acting competitively or noncompetitively at the N-methyl-D-aspartate receptor after a short period of incomplete ischaemia and evaluated selective neuronal loss in the CA1 region of the rat hippocampus. The competitive antagonists D-(–)-2-amino-7-phosphonoheptanoate...

Full description

Saved in:
Bibliographic Details
Published in:Journal of cerebral blood flow and metabolism 1990-05, Vol.10 (3), p.343-351
Main Authors: Swan, Jeanette H., Meldrum, Brian S.
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c4303-5b17467fecf6564101425b690308bd64777fb90fae92a5427ee8f19fd0b43ec63
cites cdi_FETCH-LOGICAL-c4303-5b17467fecf6564101425b690308bd64777fb90fae92a5427ee8f19fd0b43ec63
container_end_page 351
container_issue 3
container_start_page 343
container_title Journal of cerebral blood flow and metabolism
container_volume 10
creator Swan, Jeanette H.
Meldrum, Brian S.
description We have administered antagonists acting competitively or noncompetitively at the N-methyl-D-aspartate receptor after a short period of incomplete ischaemia and evaluated selective neuronal loss in the CA1 region of the rat hippocampus. The competitive antagonists D-(–)-2-amino-7-phosphonoheptanoate (2APH); 100 or 330 mg/kg; 3-(2-carboxypiperazin-4-yl)propyl-1-phosphonate (CPP); 3.3 or 10 mg/kg; and CGS 19755 (cis-4-phosphonomethyl-2-piperidine carboxylate) 3.3 or 10 mg/kg; and the noncompetitive antagonists MK801 {(+)5-methyl-10, 11-dihydro-5H-dibenzo[a,d]cyclohepten-5,10-imine maleate}, 0.3, 1, or 3 mg/kg, and dextrorphan, 2, 6, 18, or 54 mg/kg, were administered intraperitoneally 15 min and 5 h after a 10-min incomplete ischaemia period; additionally MK801 (1 or 3 mg/kg) and CGS 19755 (10 or 30 mg/kg) were administered 5 and 10 h postischaemia. Seven days after ischaemia, the brains were fixed by perfusion. CA1 pyramidal cell counts were performed on Nissl-stained sections using an ocular grid piece. Ventilated (no ischaemia) control animals had a mean of 406 ± 13 CA1 neurones/3 grid lengths. Ischaemia reduced this mean to 157 ± 23. A significant protective effect against this cell loss was seen after two injections (at 15 min and 5 h postischaemia) of 2APH, CPP (10 mg/kg), CGS 19755 (10 mg/kg), MK801 (1 mg/kg), and dextrorphan (54 mg/kg). Delayed injection (5 and 10 h postischaemia) of CGS 19755 (10 and 30 mg/kg) and MK801 (1 and 3 mg/kg) did not provide any protection against pyramidal cell loss.
doi_str_mv 10.1038/jcbfm.1990.63
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_79736298</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sage_id>10.1038_jcbfm.1990.63</sage_id><sourcerecordid>15677800</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4303-5b17467fecf6564101425b690308bd64777fb90fae92a5427ee8f19fd0b43ec63</originalsourceid><addsrcrecordid>eNqF0EtvEzEUBWALgUooLFkimQUskCbY4_cyChQqhYdEkbobeZzr4GjGLvYMqP8ep4nKCrHy4n469_og9JySJSVMv9273o9LagxZSvYALagQplGEyodoQVpFG6n09WP0pJQ9IUQzIc7QWUuF5sYs0PXXnCZwU0gR97f486d3K7yKk92lGMpU8GpnQywT_gbDQf0CvIZhwJtUCr5Iw5B-h7jDV9nGEiBO-LK4HxbGYJ-iR94OBZ6d3nP0_eL91fpjs_ny4XK92jSOM8Ia0VPFpfLgvBSSU0J5K3ppCCO630qulPK9Id6Caa3grQLQnhq_JT1n4CQ7R6-PuTc5_ZyhTN0Yiqs32ghpLp0yisnW6P9CKqRSmpAKmyN0uf4yg-9uchhtvu0o6Q6Vd3eVd4fKO8mqf3EKnvsRtvf61HGdvzrNbXF28LUrF8rfUCNaxTWt7s3RFbuDbp_mHGtx_1z68oijneYM92l36oCq-QNrXKKh</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>15677800</pqid></control><display><type>article</type><title>Protection by NMDA Antagonists Against Selective Cell Loss Following Transient Ischaemia</title><source>SAGE Deep Backfile Upgrade 2016</source><creator>Swan, Jeanette H. ; Meldrum, Brian S.</creator><creatorcontrib>Swan, Jeanette H. ; Meldrum, Brian S.</creatorcontrib><description>We have administered antagonists acting competitively or noncompetitively at the N-methyl-D-aspartate receptor after a short period of incomplete ischaemia and evaluated selective neuronal loss in the CA1 region of the rat hippocampus. The competitive antagonists D-(–)-2-amino-7-phosphonoheptanoate (2APH); 100 or 330 mg/kg; 3-(2-carboxypiperazin-4-yl)propyl-1-phosphonate (CPP); 3.3 or 10 mg/kg; and CGS 19755 (cis-4-phosphonomethyl-2-piperidine carboxylate) 3.3 or 10 mg/kg; and the noncompetitive antagonists MK801 {(+)5-methyl-10, 11-dihydro-5H-dibenzo[a,d]cyclohepten-5,10-imine maleate}, 0.3, 1, or 3 mg/kg, and dextrorphan, 2, 6, 18, or 54 mg/kg, were administered intraperitoneally 15 min and 5 h after a 10-min incomplete ischaemia period; additionally MK801 (1 or 3 mg/kg) and CGS 19755 (10 or 30 mg/kg) were administered 5 and 10 h postischaemia. Seven days after ischaemia, the brains were fixed by perfusion. CA1 pyramidal cell counts were performed on Nissl-stained sections using an ocular grid piece. Ventilated (no ischaemia) control animals had a mean of 406 ± 13 CA1 neurones/3 grid lengths. Ischaemia reduced this mean to 157 ± 23. A significant protective effect against this cell loss was seen after two injections (at 15 min and 5 h postischaemia) of 2APH, CPP (10 mg/kg), CGS 19755 (10 mg/kg), MK801 (1 mg/kg), and dextrorphan (54 mg/kg). Delayed injection (5 and 10 h postischaemia) of CGS 19755 (10 and 30 mg/kg) and MK801 (1 and 3 mg/kg) did not provide any protection against pyramidal cell loss.</description><identifier>ISSN: 0271-678X</identifier><identifier>EISSN: 1559-7016</identifier><identifier>DOI: 10.1038/jcbfm.1990.63</identifier><identifier>PMID: 2158499</identifier><identifier>CODEN: JCBMDN</identifier><language>eng</language><publisher>London, England: SAGE Publications</publisher><subject>2-Amino-5-phosphonovalerate - analogs &amp; derivatives ; Amino Acids - pharmacology ; Animals ; Anticonvulsants - metabolism ; Anticonvulsants - pharmacology ; Aspartic Acid - analogs &amp; derivatives ; Aspartic Acid - antagonists &amp; inhibitors ; Aspartic Acid - metabolism ; Biological and medical sciences ; Brain - pathology ; Brain Ischemia - metabolism ; Dibenzocycloheptenes - pharmacology ; Dizocilpine Maleate ; Male ; Medical sciences ; Miscellaneous ; N-Methylaspartate ; Neurons - pathology ; Neuropharmacology ; Pharmacology. Drug treatments ; Pipecolic Acids ; Piperazines - pharmacology ; Piperidines - pharmacology ; Rats ; Rats, Inbred Strains ; Receptors, N-Methyl-D-Aspartate ; Receptors, Neurotransmitter - drug effects ; Receptors, Neurotransmitter - metabolism</subject><ispartof>Journal of cerebral blood flow and metabolism, 1990-05, Vol.10 (3), p.343-351</ispartof><rights>1990 International Society for Cerebral Blood Flow and Metabolism</rights><rights>1991 INIST-CNRS</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4303-5b17467fecf6564101425b690308bd64777fb90fae92a5427ee8f19fd0b43ec63</citedby><cites>FETCH-LOGICAL-c4303-5b17467fecf6564101425b690308bd64777fb90fae92a5427ee8f19fd0b43ec63</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://journals.sagepub.com/doi/pdf/10.1038/jcbfm.1990.63$$EPDF$$P50$$Gsage$$H</linktopdf><linktohtml>$$Uhttps://journals.sagepub.com/doi/10.1038/jcbfm.1990.63$$EHTML$$P50$$Gsage$$H</linktohtml><link.rule.ids>314,780,784,21860,27924,27925,44857,45245</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=19527481$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/2158499$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Swan, Jeanette H.</creatorcontrib><creatorcontrib>Meldrum, Brian S.</creatorcontrib><title>Protection by NMDA Antagonists Against Selective Cell Loss Following Transient Ischaemia</title><title>Journal of cerebral blood flow and metabolism</title><addtitle>J Cereb Blood Flow Metab</addtitle><description>We have administered antagonists acting competitively or noncompetitively at the N-methyl-D-aspartate receptor after a short period of incomplete ischaemia and evaluated selective neuronal loss in the CA1 region of the rat hippocampus. The competitive antagonists D-(–)-2-amino-7-phosphonoheptanoate (2APH); 100 or 330 mg/kg; 3-(2-carboxypiperazin-4-yl)propyl-1-phosphonate (CPP); 3.3 or 10 mg/kg; and CGS 19755 (cis-4-phosphonomethyl-2-piperidine carboxylate) 3.3 or 10 mg/kg; and the noncompetitive antagonists MK801 {(+)5-methyl-10, 11-dihydro-5H-dibenzo[a,d]cyclohepten-5,10-imine maleate}, 0.3, 1, or 3 mg/kg, and dextrorphan, 2, 6, 18, or 54 mg/kg, were administered intraperitoneally 15 min and 5 h after a 10-min incomplete ischaemia period; additionally MK801 (1 or 3 mg/kg) and CGS 19755 (10 or 30 mg/kg) were administered 5 and 10 h postischaemia. Seven days after ischaemia, the brains were fixed by perfusion. CA1 pyramidal cell counts were performed on Nissl-stained sections using an ocular grid piece. Ventilated (no ischaemia) control animals had a mean of 406 ± 13 CA1 neurones/3 grid lengths. Ischaemia reduced this mean to 157 ± 23. A significant protective effect against this cell loss was seen after two injections (at 15 min and 5 h postischaemia) of 2APH, CPP (10 mg/kg), CGS 19755 (10 mg/kg), MK801 (1 mg/kg), and dextrorphan (54 mg/kg). Delayed injection (5 and 10 h postischaemia) of CGS 19755 (10 and 30 mg/kg) and MK801 (1 and 3 mg/kg) did not provide any protection against pyramidal cell loss.</description><subject>2-Amino-5-phosphonovalerate - analogs &amp; derivatives</subject><subject>Amino Acids - pharmacology</subject><subject>Animals</subject><subject>Anticonvulsants - metabolism</subject><subject>Anticonvulsants - pharmacology</subject><subject>Aspartic Acid - analogs &amp; derivatives</subject><subject>Aspartic Acid - antagonists &amp; inhibitors</subject><subject>Aspartic Acid - metabolism</subject><subject>Biological and medical sciences</subject><subject>Brain - pathology</subject><subject>Brain Ischemia - metabolism</subject><subject>Dibenzocycloheptenes - pharmacology</subject><subject>Dizocilpine Maleate</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Miscellaneous</subject><subject>N-Methylaspartate</subject><subject>Neurons - pathology</subject><subject>Neuropharmacology</subject><subject>Pharmacology. Drug treatments</subject><subject>Pipecolic Acids</subject><subject>Piperazines - pharmacology</subject><subject>Piperidines - pharmacology</subject><subject>Rats</subject><subject>Rats, Inbred Strains</subject><subject>Receptors, N-Methyl-D-Aspartate</subject><subject>Receptors, Neurotransmitter - drug effects</subject><subject>Receptors, Neurotransmitter - metabolism</subject><issn>0271-678X</issn><issn>1559-7016</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1990</creationdate><recordtype>article</recordtype><recordid>eNqF0EtvEzEUBWALgUooLFkimQUskCbY4_cyChQqhYdEkbobeZzr4GjGLvYMqP8ep4nKCrHy4n469_og9JySJSVMv9273o9LagxZSvYALagQplGEyodoQVpFG6n09WP0pJQ9IUQzIc7QWUuF5sYs0PXXnCZwU0gR97f486d3K7yKk92lGMpU8GpnQywT_gbDQf0CvIZhwJtUCr5Iw5B-h7jDV9nGEiBO-LK4HxbGYJ-iR94OBZ6d3nP0_eL91fpjs_ny4XK92jSOM8Ia0VPFpfLgvBSSU0J5K3ppCCO630qulPK9Id6Caa3grQLQnhq_JT1n4CQ7R6-PuTc5_ZyhTN0Yiqs32ghpLp0yisnW6P9CKqRSmpAKmyN0uf4yg-9uchhtvu0o6Q6Vd3eVd4fKO8mqf3EKnvsRtvf61HGdvzrNbXF28LUrF8rfUCNaxTWt7s3RFbuDbp_mHGtx_1z68oijneYM92l36oCq-QNrXKKh</recordid><startdate>199005</startdate><enddate>199005</enddate><creator>Swan, Jeanette H.</creator><creator>Meldrum, Brian S.</creator><general>SAGE Publications</general><general>Lippincott Williams &amp; Wilkins</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7TK</scope><scope>7X8</scope></search><sort><creationdate>199005</creationdate><title>Protection by NMDA Antagonists Against Selective Cell Loss Following Transient Ischaemia</title><author>Swan, Jeanette H. ; Meldrum, Brian S.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4303-5b17467fecf6564101425b690308bd64777fb90fae92a5427ee8f19fd0b43ec63</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1990</creationdate><topic>2-Amino-5-phosphonovalerate - analogs &amp; derivatives</topic><topic>Amino Acids - pharmacology</topic><topic>Animals</topic><topic>Anticonvulsants - metabolism</topic><topic>Anticonvulsants - pharmacology</topic><topic>Aspartic Acid - analogs &amp; derivatives</topic><topic>Aspartic Acid - antagonists &amp; inhibitors</topic><topic>Aspartic Acid - metabolism</topic><topic>Biological and medical sciences</topic><topic>Brain - pathology</topic><topic>Brain Ischemia - metabolism</topic><topic>Dibenzocycloheptenes - pharmacology</topic><topic>Dizocilpine Maleate</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Miscellaneous</topic><topic>N-Methylaspartate</topic><topic>Neurons - pathology</topic><topic>Neuropharmacology</topic><topic>Pharmacology. Drug treatments</topic><topic>Pipecolic Acids</topic><topic>Piperazines - pharmacology</topic><topic>Piperidines - pharmacology</topic><topic>Rats</topic><topic>Rats, Inbred Strains</topic><topic>Receptors, N-Methyl-D-Aspartate</topic><topic>Receptors, Neurotransmitter - drug effects</topic><topic>Receptors, Neurotransmitter - metabolism</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Swan, Jeanette H.</creatorcontrib><creatorcontrib>Meldrum, Brian S.</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Neurosciences Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of cerebral blood flow and metabolism</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Swan, Jeanette H.</au><au>Meldrum, Brian S.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Protection by NMDA Antagonists Against Selective Cell Loss Following Transient Ischaemia</atitle><jtitle>Journal of cerebral blood flow and metabolism</jtitle><addtitle>J Cereb Blood Flow Metab</addtitle><date>1990-05</date><risdate>1990</risdate><volume>10</volume><issue>3</issue><spage>343</spage><epage>351</epage><pages>343-351</pages><issn>0271-678X</issn><eissn>1559-7016</eissn><coden>JCBMDN</coden><abstract>We have administered antagonists acting competitively or noncompetitively at the N-methyl-D-aspartate receptor after a short period of incomplete ischaemia and evaluated selective neuronal loss in the CA1 region of the rat hippocampus. The competitive antagonists D-(–)-2-amino-7-phosphonoheptanoate (2APH); 100 or 330 mg/kg; 3-(2-carboxypiperazin-4-yl)propyl-1-phosphonate (CPP); 3.3 or 10 mg/kg; and CGS 19755 (cis-4-phosphonomethyl-2-piperidine carboxylate) 3.3 or 10 mg/kg; and the noncompetitive antagonists MK801 {(+)5-methyl-10, 11-dihydro-5H-dibenzo[a,d]cyclohepten-5,10-imine maleate}, 0.3, 1, or 3 mg/kg, and dextrorphan, 2, 6, 18, or 54 mg/kg, were administered intraperitoneally 15 min and 5 h after a 10-min incomplete ischaemia period; additionally MK801 (1 or 3 mg/kg) and CGS 19755 (10 or 30 mg/kg) were administered 5 and 10 h postischaemia. Seven days after ischaemia, the brains were fixed by perfusion. CA1 pyramidal cell counts were performed on Nissl-stained sections using an ocular grid piece. Ventilated (no ischaemia) control animals had a mean of 406 ± 13 CA1 neurones/3 grid lengths. Ischaemia reduced this mean to 157 ± 23. A significant protective effect against this cell loss was seen after two injections (at 15 min and 5 h postischaemia) of 2APH, CPP (10 mg/kg), CGS 19755 (10 mg/kg), MK801 (1 mg/kg), and dextrorphan (54 mg/kg). Delayed injection (5 and 10 h postischaemia) of CGS 19755 (10 and 30 mg/kg) and MK801 (1 and 3 mg/kg) did not provide any protection against pyramidal cell loss.</abstract><cop>London, England</cop><pub>SAGE Publications</pub><pmid>2158499</pmid><doi>10.1038/jcbfm.1990.63</doi><tpages>9</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0271-678X
ispartof Journal of cerebral blood flow and metabolism, 1990-05, Vol.10 (3), p.343-351
issn 0271-678X
1559-7016
language eng
recordid cdi_proquest_miscellaneous_79736298
source SAGE Deep Backfile Upgrade 2016
subjects 2-Amino-5-phosphonovalerate - analogs & derivatives
Amino Acids - pharmacology
Animals
Anticonvulsants - metabolism
Anticonvulsants - pharmacology
Aspartic Acid - analogs & derivatives
Aspartic Acid - antagonists & inhibitors
Aspartic Acid - metabolism
Biological and medical sciences
Brain - pathology
Brain Ischemia - metabolism
Dibenzocycloheptenes - pharmacology
Dizocilpine Maleate
Male
Medical sciences
Miscellaneous
N-Methylaspartate
Neurons - pathology
Neuropharmacology
Pharmacology. Drug treatments
Pipecolic Acids
Piperazines - pharmacology
Piperidines - pharmacology
Rats
Rats, Inbred Strains
Receptors, N-Methyl-D-Aspartate
Receptors, Neurotransmitter - drug effects
Receptors, Neurotransmitter - metabolism
title Protection by NMDA Antagonists Against Selective Cell Loss Following Transient Ischaemia
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-29T14%3A00%3A41IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Protection%20by%20NMDA%20Antagonists%20Against%20Selective%20Cell%20Loss%20Following%20Transient%20Ischaemia&rft.jtitle=Journal%20of%20cerebral%20blood%20flow%20and%20metabolism&rft.au=Swan,%20Jeanette%20H.&rft.date=1990-05&rft.volume=10&rft.issue=3&rft.spage=343&rft.epage=351&rft.pages=343-351&rft.issn=0271-678X&rft.eissn=1559-7016&rft.coden=JCBMDN&rft_id=info:doi/10.1038/jcbfm.1990.63&rft_dat=%3Cproquest_cross%3E15677800%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c4303-5b17467fecf6564101425b690308bd64777fb90fae92a5427ee8f19fd0b43ec63%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=15677800&rft_id=info:pmid/2158499&rft_sage_id=10.1038_jcbfm.1990.63&rfr_iscdi=true